MDxHealth SA (NASDAQ:MDXH) Brief Interest Update
MDxHealth SA (NASDAQ:MDXH – Get Rating) benefited from strong short-term interest growth in June. As of June 30, there were short interests totaling 6,600 shares, an 88.6% growth from the total of 3,500 shares as of June 15. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume of 54,300 shares, the short-term interest rate ratio is currently 0.1 day.
MDxHealth trades up 1.4%
Shares of NASDAQ:MDXH traded at $0.10 in Friday’s midday session, hitting $7.10. 6,352 shares of the company were traded, against an average volume of 6,333. The company’s 50-day simple moving average is $7.60 and its two-hundred-day simple moving average is $8.19 . The company has a quick ratio of 3.94, a current ratio of 4.05 and a leverage ratio of 0.22. MDxHealth has a fifty-two week minimum of $6.20 and a fifty-two week maximum of $13.17.
MDxHealth (NASDAQ:MDXH – Get Rating) last released its quarterly earnings data on Wednesday, April 27. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($0.55) by $0.50. The company posted revenue of $6.11 million for the quarter, versus analyst estimates of $8.85 million. On average, research analysts expect MDxHealth to post earnings per share of -2.09 for the current year.
Hedge funds weigh on MDxHealth
Institutional investors have recently been buying and selling shares of the company. Ghisallo Capital Management LLC bought a new stock position in MDxHealth in Q4 worth approximately $190,000. Altium Capital Management LP bought a new stock position in MDxHealth in Q4, valued at around $344,000. Perkins Capital Management Inc. bought a new stock position in MDxHealth in Q4, valued at approximately $857,000. Finally, Bleichroeder LP bought a new stock position in MDxHealth in Q4 valued at approximately $18,643,000. 18.16% of the shares are held by institutional investors and hedge funds.
Wall Street analysts predict growth
Separately, BTIG Research restated a “buy” rating and issued a $13.00 price target on MDxHealth shares in a Friday, April 29 report.
(Get an assessment)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urology solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union and the rest of the European Union. ‘international. Its new prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provides physicians with a clinical pathway to clinically identify prostate cancer while minimizing the use of complication-prone invasive procedures.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in MDxHealth right now?
Before you consider MDxHealth, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and MDxHealth wasn’t on the list.
Although MDxHealth currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here